<DOC>
	<DOCNO>NCT00376181</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pioglitazone-azilsartan , daily ( QD ) , subject type 2 diabetes mellitus poor glycemic control .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Pioglitazone-Azilsartan Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Type 2 diabetes chronic disease . In United States , estimate 21 million people diabetes , type 2 diabetes occur 90 % 95 % case . Hypertension ( high blood pressure ) affect approximately 50 million individual United States . The association diabetes hypertension increase population ; hypertension common person diabetes individual hypertension 2.5 time likely develop diabetes normal blood pressure . As result , 70 % adult diabetes hypertension ( define blood pressure great equal 130/80 mm Hg use prescription medication hypertension ) . Patients type 2 diabetes hypertension high risk illness death . Diabetes hypertension associate insulin resistance ( normal amount insulin adequate produce normal insulin response fat , muscle liver cell ) . hyperinsulinemia ( excess level insulin blood ) , independent risk factor cardiovascular ( heart vessel ) disease . Individuals type 2 diabetes carry 2 4- time great risk cardiovascular disease stroke compare general population . Uncontrolled hypertension also associate increase risk cardiovascular disease stroke . Takeda Global Research Development Center , Inc. develop fixed-dose combination product , AD-4833-536 . AD-4833-536 combination AD-4833 ( pioglitazone ) TAK-536 ( azilsartan ) . Pioglitazone oral antidiabetic agent act reduce insulin resistance approve treatment adult patient type 2 diabetes mellitus . Azilsartan angiotensin II receptor blocker modulate renin-angiotensin-aldosterone system regulate blood pressure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion Criteria Type 2 diabetes glycosylated hemoglobin great equal 9.0 less equal 11.0 % Screening . Documented hypertension . On stable diet exercise program addition metformin alone combination metformin sulfonylurea minimum 8 week prior screen . If receive antihypertensive therapy , must 3 agent stable regimen . Clinical laboratory evaluation ( include clinical chemistry , hematology , urinalysis ) within reference range unless result deem clinically significant inclusion study investigator . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Exclusion Criteria Type 1 diabetes mellitus . Diastolic blood pressure great 104 mm Hg randomization visit . Currently take angiotensin IIreceptor blocker . Unstable angina heart failure etiology New York Heart Association functional class III IV . History myocardial infarction , cerebrovascular accident ( stroke ) , percutaneous coronary intervention , coronary artery bypass graft transient ischemic attack within previous six month . Clinically significant cardiac conduction defect . Secondary hypertension etiology . Body mass index great 45 kg/m2 Has significant renal dysfunction . History drug abuse history alcohol abuse within past 2 year . Previous history cancer , basal cell carcinoma stage 1 squamous cell carcinoma skin remission least 5 year prior first dose study drug . Alanine transaminase aspartate transaminase level great 2.5 time upper limit normal , active liver disease , jaundice . Serum potassium great upper limit normal . Currently participate another investigational study participate investigational study within 30 day prior Randomization . Any serious disease condition would compromise subject safety , might affect life expectancy , make difficult successfully manage follow subject accord protocol . Is hypersensitive angiotensin II receptor blocker . Is hypersensitive thiazolidinediones . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : antidiabetic agent ( include thiazolidinediones and/or insulin ) except metformin combination metformin sulfonylurea niacin 200mg per day tricyclic antidepressant phenothiazine Angiotensin II receptor blocker Thiazolidinediones Insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>diastolic blood pressure</keyword>
</DOC>